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Abstract
Background: Indigenous Australians have high rates of diabetes and its complications. This study
examines ethnic differences in the management of patients with type 2 diabetes in Australian
primary care.
Methods: Diabetes management and outcomes in Indigenous patients enrolled in the NEFRON
study (n = 144) was systematically compared with that in non-Indigenous patients presenting
consecutively to the same practitioner (n = 449), and the NEFRON cohort as a whole (n = 3893).
Results: Indigenous Australians with diabetes had high rates of micro- and macrovascular disease.
60% of Indigenous patients had an abnormal albumin to creatinine ratio compared to 33% of non-
Indigenous patients (p < 0.01). When compared to non-Indigenous patients, Indigenous patients
were more likely to have established macrovascular disease ((adjusted Odds ratio 2.7). This excess
in complications was associated with poor glycemic control, with an HbA1c ≥ 8.0%, observed in 55%
of all Indigenous patients, despite the similar frequency use of oral antidiabetic agents and insulin.
Smoking was also more common in Indigenous patients (38%vs 10%, p < 0.01). However, the
achievement of LDL and blood pressure targets was the same or better in Indigenous patients.
Conclusion: Although seeing the same doctors and receiving the same medications, glycaemic and
smoking cessation targets remain unfulfilled in Indigenous patients. This cross-sectional study
confirms Aboriginal ethnicity as a powerful risk factor for microvascular and macrovascular disease,
which practitioners should use to identify candidates for intensive multifactorial intervention.
Background
Indigenous Australians have high rates of diabetes and its
complications, including blindness[1], kidney disease[2],
and cardiovascular mortality[3]. The reasons for this racial
disparity are multifactorial, involving a complex interplay
of behavioural, biological, economic and societal factors
that vary across health indicators and healthcare settings.
One confounding factor is the quality of diabetes care
delivered in populations that are culturally and socio-eco-
nomically disadvantaged [4,5]. Indeed, the fact that
minority patients, such as Indigenous Australians, are
more likely to receive care at lower-performing facilities in
remote and regional sites has biased many comparative
studies. Moreover, when controlled for in managed-care
settings, ethnicity is not consistently associated with
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worse processes or outcomes in individuals with type 2
diabetes [4].
The National Evaluation of the Frequency of Renal
Impairment cO-existing with NIDDM (NEFRON) study
was an large national survey of patients with type 2 diabe-
tes in the Australian primary care setting [6]. The principal
aim of this clinic-based study was to determine the fre-
quency of any consultation between any patient with type
2 diabetes and their general practitioner to be complicated
by chronic kidney disease, and the factors that influence
it's management. In this paper, we examine the manage-
ment of patients identified by their GP as having an Indig-
enous ethnic background, and contrast it with the care of
non-Indigenous patients consecutively presenting to the
same practice, and over the total NEFRON cohort.
Methods
Study design
NEFRON was an clinic-based, cluster-stratified survey of
patients with type 2 diabetes in the Australian primary
care setting. It represents the collaborative effort of Kidney
Health Australia, the Baker Heart Research Institute, Serv-
ier (Australia) and participating investigators. Data collec-
tion and analysis were managed externally by Quintiles
SRS and Statistical Revelations, Melbourne. The principal
aim of the study was to determine, in the general practice
setting, the prevalence of impaired kidney function in
individuals with established type 2 diabetes. The Royal
Australian College of General Practitioners (RACGP)
National Research and Evaluation Ethics Committee
approved the study and written informed consent was
obtained from all participating patients.
Sampling and investigator selection
The recruitment of investigators and sample selection are
described in detail elsewhere [6,7] and are briefly summa-
rised below. Expressions of interest (EOIs) were invited
via a mailing from all (18810) registered GPs across all
jurisdictions in Australia in February 2005. EOIs were
stratified according to location within each state in a clas-
sification derived from Australian Rural, Remote and Met-
ropolitan Area categories. A number of EOIs from each
stratum, proportional to the census population (Austral-
ian Bureau of Statistics, 2001), were then randomly
selected (SPSS V13.0, Quintiles), to make up a total of 500
GP investigators nationally. In the event that a cohort did
not achieve target levels of GP registration, re-mailing tar-
geted by sector was employed. In the event of investigator
withdrawal from the study, the geographically closest, but
not previously selected, EOI was approached as a poten-
tial replacement. The final investigators recruited had a
mean age, gender distribution, professional qualifications
and number of sessions per week that was not signifi-
cantly different to that recorded for the all registered gen-
eral practitioners in Australia [6,7].
Target population/eligibility requirements
During their own routine practice, selected NEFRON
investigators were requested to recruit 10–15 consecu-
tively presenting adult patients (18 years of age or older)
with established type 2 diabetes, irrespective of reason for
visit. Patients were required to give written informed con-
sent in English. Consecutive persons with disabilities that
precluded participation in the study, or those declining to
participate in the study were not included.
Survey protocol and procedures
Data collection took place between April and September,
2005. A de-identified case report form was completed for
each eligible patient, which captured demographic infor-
mation including age, gender, ethnicity, history of dia-
betic complications, medication usage, smoking and
relevant family history. Additionally, the results of routine
physical examination were provided (height, weight,
waist circumference, blood pressure [seated, right arm,
diastolic at Korotkov phase V], and data from the most
recent blood tests and urinalysis, including serum creati-
nine, urea and electrolytes, HbA1c, fasting glucose and lip-
ids, urinary albumin and creatinine. Tests were repeated at
the study visit if no recent (within 3 months) result was
available. No attempt was made to standardise results
from different laboratories or regions, but rather to docu-
ment the raw results on which practitioners base their
assessment and management.
Patient stratification
For the purpose of this analysis, the management of dia-
betic patients identified by their GP as having Aboriginal
or Torres Strait Island ethnicity (n = 144), was compared
with that received by non-Indigenous patients presenting
consecutively to the same practitioner (n = 449), and as
well as to that of the total NEFRON cohort.
Definitions used
For the purposes of analysis, glycaemic control was han-
dled as a categorical variable, with poor glycaemic control
denoted by a HbA1c  above 8.0%, an optimal control
denoted by a HbA1c below 7.0%. Optimal blood pressure
control was denoted by a systolic BP less than 130 mmHg.
Optimal lipid control was denoted by achieved IDF treat-
ment targets of an LDL < 2.5 mmol/L, an HDL > 1.0
mmol/L, and triglycerides less than 2.3 mmol/L.
The presence of Chronic Kidney disease (CKD) was
defined according to standard Kidney Disease Outcomes
Quality Initiative (K/DOQI) guidelines, such that individ-
uals with an estimated glomerular filtration rate (eGFR) of
less than 60 ml/min/1.73 m2 or with evidence of kidneyBMC Public Health 2007, 7:303 http://www.biomedcentral.com/1471-2458/7/303
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damage on urinalysis (e.g. microalbuminuria) were said
to have CKD. For primary analyses, the presence of an
eGFR of less than 60 ml/min/1.73 m2 was determined as
a categorical variable using the MDRD-4 formula, which
has been shown to be a reliable tool for the determination
of impaired kidney function in Australian patients with
type 2 diabetes[8]. Albuminuria was stratified according
to Australian and International Diabetes Federation
guidelines [9,10], such that women with a urinary ACR of
less than 3.5 g/mol and men less than 2.5 g/mol were con-
sidered to have Normoalbuminuria. Microalbuminuria
was defined in women by a urinary ACR of 3.5 to 35 g/
mol and in men by a urinary ACR of 2.5 to 25 g/mol. Mac-
roalbuminuria was defined by a urinary ACR of greater
than 35 g/mol in women and greater than 25 g/mol in
men. Patients with macro- or microalbuminuria were said
to have elevated urinary albumin excretion. Macrovascu-
lar disease was defined at the presence of any of cardiovas-
cular disease, cerebrovascular disease or peripheral
vascular disease.
Data handling and Statistical Methods
Continuous data are expressed as their mean ± standard
error (SEM). Categorical data are expressed as their fre-
quency (%) in the cohort or subgroup. Analyses for nom-
inal variables consisted of either one-way analysis of
variance (ANOVA) for single variables or two-way
ANOVA for comparison of three groups. Sub analyses for
categorical variables involved Pearson Chi-Square analy-
sis of proportions between independent parameters. The
independent influence of Indigenous ethnicity on glycae-
mic and blood pressure control and on the frequency of
diabetic complications, was assessed by multivariate
logistic regression analysis, adjusting for differences in
baseline parameters including age, gender, duration of
diabetes, smoking history, obesity, and the type and
intensity of glycaemic, antihypertensive and lipid control.
In addition, to correct for potential clustering of responses
within practices, confidence intervals and statistical signif-
icance were estimated using a sandwich variance-covari-
ance matrix. Multivariate associations are expressed as an
adjusted odds ratio [95% confidence interval (CI)].
Results
Patient characteristics
Data and informed consent were obtained from 3893
adults with type 2 diabetes. The clinical characteristics of
this cohort have been previously published[6,7], and are
similar to that observed in other Australian studies of
patients with type 2 diabetes. Briefly, patient had a mean
age of 66 years and a median duration of diagnosed dia-
betes of six years. Fifty-two percent of all patients were
male. 144 patients (3.7%) were identified by their practi-
tioner as Indigenous Australians. These patients came
from 51 different practices from urban, rural and remote
settings throughout Australia (figure 1). These same prac-
tices recorded clinical data on 449 non-Indigenous
patients presenting consecutively with Indigenous
patients in their practices. The non-indigenous control
group was predominantly Caucasian (87%), but included
patients of Asian (10%) and other ethnic backgrounds.
The clinical characteristics of both these patient groups,
and the NEFRON cohort as a whole are detailed in table
1. While all patients had a similar duration of diagnosed
diabetes, Indigenous patients were approximately 10
years younger and more often female than other diabetic
patients in the same practice or the cohort as a whole
(table 1). Indigenous patients also were more likely to
have a first-degree relative with diabetes compared to
non-Indigenous patients presenting consecutively (68%
vs 34%, p < 0.01).
Glycaemic control in Indigenous patients
Metabolic control was significantly worse in Indigenous
patients than other diabetic patients in the same practice
or the NEFRON cohort as a whole. While 48% of all
NEFRON patients achieved HbA1c targets of < 7.0%, these
targets were achieved in only 24% of Indigenous patients.
Moreover, Indigenous Australians were more likely to
have an HbA1c ≥ 8.0% (55%) when compared to Cauca-
sian (23%) or Asian patients in the NEFRON survey
(23%). This excess persisted after adjusting for other risk
factors for poor glycaemic control (adjusted odds ratio
2.8; 95% CI 2.0 – 4.3). In addition, the use of oral antidi-
abetic agents, alone or in combination, and insulin was
similar, in all ethnic groups (table 1).
When asked to categorise their patient's glycaemic con-
trol, on the basis of current results, 52% of NEFRON
patients were perceived by their GP as having 'optimal
control', including 28% of Indigenous patients. In both
Indigenous and non-Indigenous patients, this categorisa-
tion closely concurred with a target HbA1c of 7.0% (kappa
statistic for agreement = 0.76), suggesting that practition-
ers were not complacent about poor glycaemic control in
their Indigenous patients.
Blood pressure control in Indigenous patients
While mean blood pressure levels were similar in the
NEFRON cohort regardless of ethnicity (table 1), more
Indigenous patients achieved treatment targets of systolic
BP < 130 mmHg (44%) when compared to 33% in the
NEFRON cohort (p = 0.01). This was partly explained by
the fact that Indigenous patient were generally younger,
and had a shorter duration of diabetes (table 1). After
adjusting for these variables, Indigenous patients were
equally likely to achieve treatment targets (adjusted Odds
ratio 1.1; 95% CI 0.8 – 1.4). At the same time, GPs identi-
fied the BP to be 'optimally controlled' in 66% of Indige-
nous patients, compared to 65% in the cohort as a whole.BMC Public Health 2007, 7:303 http://www.biomedcentral.com/1471-2458/7/303
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The percentage of subjects prescribed agents that block the
RAS were also similar to the cohort as a whole. However,
Indigenous patients were less likely to be receiving multi-
ple antihypertensive agents (27%) compared to other dia-
betic patients presenting at the same centre (40%) or in
the cohort as a whole (43%).
Lipid levels in Indigenous patients
Total cholesterol levels were generally similar in Indige-
nous patients when compared to diabetic patients in the
same practice or to the NEFRON cohort as a whole (table
1). 53% achieved treatment targets of LDL < 2.5 mmol/L
compared to 54% in the NEFRON cohort, and this iden-
tity persisted after adjusting for baseline differences
(adjusted Odds ratio 1.1; 95% CI 0.7 – 1.6). A similar
number of both Indigenous and non-Indigenous patients
also received lipid-lowering therapies. However, Indige-
nous patients were more likely to have a low HDL (<1.0
mmol; 39% vs 21% in non-Indigenous patients seen con-
secutively at the same practice and 16% in the cohort as a
whole; adjusted Odds ratio 4.0; 95% CI 2.6 – 6.0). In
addition 52% of all Indigenous patients had elevated trig-
lycerides (≥ 2.3 mmol/L) compared to 26% of the
NEFRON cohort as a whole (adjusted Odds ratio Odds
ratio 2.7; 95% CI 1.8 – 3.6).
Microvascular Disease in Indigenous patients
Indigenous patients had high rates of CKD, despite the
same median duration of diabetes. In particular, 23% of
Indigenous patients with type 2 diabetes had a urinary
ACR in the macroalbuminuric range, compared to 6% of
non-Indigenous patients in the same practice or 7% in the
NEFRON cohort as a whole. Overall, after adjusting for
baseline differences, Indigenous patients presenting to
their GP were significantly more likely to have an
increased urinary albumin excretion (adjusted Odds ratio
5.2; 95% CI 3.6 – 4.6). This excess in renal disease was
clearly familial, as 38% of Indigenous patients had first-
degree relative with CKD, compared to less than 8% of
non-Indigenous patients presenting consecutively. How-
ever, this excess of Indigenous patients with had an ele-
vated urinary ACR could not be explained by higher
Geographic distribution of Australian practices enrolling Indigenous patients in the NEFRON study Figure 1
Geographic distribution of Australian practices enrolling Indigenous patients in the NEFRON study.BMC Public Health 2007, 7:303 http://www.biomedcentral.com/1471-2458/7/303
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albumin excretion rates more generally in Indigenous
individuals, as 28% of non-Indigenous patients with
newly-diagnosed diabetes (duration less than one year)
had an abnormal ACR compared to 32% of Indigenous
patients with newly diagnosed diabetes (figure 2).
Twenty-one percent of patients in the NEFRON survey
had a reduced eGFR (<60 ml/min/1.73 m2), regardless of
ethnicity. This was partly due to the large numbers of eld-
erly Caucasian patients with a reduced eGFR seen in Aus-
tralian medical practice and enrolled in the NEFRON
survey. However, after adjusting for baseline differences,
Indigenous patients presenting to their GP were signifi-
cantly more likely to have a reduce eGFR (adjusted Odds
ratio 2.4; 95% CI 1.4 – 3.9, figure 3). Retinopathy was also
more commonly identified in Indigenous patients (16%
vs 10%, adjusted Odds ratio 2.2; 95% CI 1.2 – 3.6), as pre-
viously reported [6,7].
Macrovascular disease in Indigenous patients
Thirty-one percent of all patients presenting to their GP in
the NEFRON study had symptomatic macrovascular dis-
ease, including 23% with cardiovascular disease (table 1).
Overall, the frequency of macrovascular disease was mar-
ginally more common in Indigenous patients compared
other patients from the same practices. This rate was not
significantly different from the NEFRON cohort as a
whole (table 1). However, after adjusting for baseline dif-
ferences, Indigenous patients were significantly more
likely to have established macrovascular disease (adjusted
Odds ratio 2.7; 95% CI 1.8 – 4.2, figure 4). This was not
attributable to the excess of CKD in this population, as a
high rate of macrovascular disease was seen in Indigenous
patients with and without CKD (35% vs 34%, p = NS).
However, 43% of Indigenous patients had first-degree rel-
ative with cardiovascular disease diagnosed before the age
of 50, compared to less than 15% of non-Indigenous
patients presenting consecutively. Indigenous patients
were also more likely to be current smokers. Despite their
increased cardiovascular risk, aspirin use in Indigenous
Table 1: Clinical characteristics of NEFRON study patients. Univariate p-value compares Indigenous versus non-Indigenous patients 
from the same practice
Indigenous Non-Indigenous 
but same practice
All NEFRON Univariate p-value
N = 144 N = 449 N = 3898
Age (years) 53 ± 1 64 ± 1 66 ± 1 <0.001
Gender (% male) 41% (40–42) 50% (50–51) 52%(51–52) 0.04
Diabetes duration (years) 8 ± 1 8 ± 1 8 ± 1 0.96
Family history of diabetes (%) 64% (58–62)* 37%(33–41) 35%(34–36) <0.001
Current smoker (%) 38% (30–46)* 9% (6–12) 10%(9–11) <0.001
Obese BMI(%) 47% (38–56) 52% (47–57) 49% (47–51) 0.31
Waist circumference (cm) 106 ± 2 105 ± 1 104 ± 1 0.48
HbA1c(%) 8.9 ± 0.1* 7.4 ± 0.1 7.3 ± 0.1 <0.001
Fasting Glucose (mmol/L) 11.0 ± 0.4* 8.0 ± 0.1 7.9 ± 0.1 <0.001
Metformin (%) 71% (64–78) 69% (65–73) 63% (61–65) 0.60
Sulphonylurea (%) 52% (44–60) 43% (38–48) 45% (43–47) 0.08
Any Insulin (%) 18% (12–24) 14% (11–17) 13% (12–15) 0.21
Antihypertensive (%) 66% (58–76) 70% (66–74) 71% (70–72) 0.47
RAS blockade (%) 76% (69–83) 69% (65–73) 71% (70–72) 0.08
Number Antihypertensives (n) 1.1 ± 0.1* 1.3 ± 0.1 1.4 ± 0.1 0.03
Blood Pressure (mmHg) 132/80 134/78 134/77 0.24/0.05
Lipid lowering therapy (%) 52%(44–60) 59%(54–64) 64%(62–66) 0.17
LDL cholesterol (mmol/L) 2.5 ± 0.1 2.6 ± 0.1 2.5 ± 0.1 0.80
HDL cholesterol (mmol/L) 1.1 ± 0.1* 1.2 ± 0.1 1.3 ± 0.1 <0.001
Triglycerides (mmol/L) 2.7 ± 0.1* 2.0 ± 0.1 2.0 ± 0.1 <0.001
Normoalbuminuria (%) 41% (33–49)* 67% (63–71) 65%(63–67) <0.001
Microalbuminuria (%) 36% (28–44)* 27% (23–31) 27%(26–28) <0.001
Macroalbuminuria (%) 23% (16–30)* 6%(4–8) 7%(6–8) <0.001
eGFR < 60 ml/min/1.73 m2 21%(14–28) 19%(14–24) 23%(21–25) 0.50
Family history of CKD (%) 38% (30–46)* 8%(5–11) 7%(6–8) <0.001
Macrovascular disease (%) 35%(27–43) 27%(23–31) 31%(30–32) 0.08
Cardiovascular disease (%) 25%(18–32) 18%(14–22) 23%(22–24) 0.10
Family history of early CVD (%) 43%(34–51) 14%(10–18) 15%(14–16) <0.001
( * p < 0.01; adjusted for age, gender and duration of diabetes)BMC Public Health 2007, 7:303 http://www.biomedcentral.com/1471-2458/7/303
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patients was similar to the NEFRON population as a
whole (~51%).
Discussion and conclusion
Despite advances in diabetes care, the clinical outcomes of
Indigenous Australians with type 2 diabetes in general
practice remain poor. While ethnic differences in the qual-
ity of diabetes care partly contributes to disparity in dia-
betic complications, even when compared to non-
Indigenous patients consecutively attending the same
practitioner and receiving a comparable pattern of care,
Aboriginal patients have worse glycemic control, and
more micro- and macrovascular complications. These
findings are consistent with smaller community-based
studies[11] and collected regional data from remote and
rural settings [12-15], where HbA1c levels are typically 1%
higher in Indigenous patients, and high rates of complica-
tions are observed. However, these data represent the first
national survey including large numbers of Indigenous
patients and adjusting for centre effects, to characterise
this disparity.
The National Evaluation of the Frequency of Renal
Impairment cO-existing with NIDDM (NEFRON) study
was an clinic-based, cluster-stratified survey of patients
with type 2 diabetes from across the Australian primary
care setting. It was not designed to be representative of all
patients with type 2 diabetes, and clearly excludes patients
outside of the mainstream of primary care (e.g. Aboriginal
Medical Services, Tertiary Care etc). Data collected as part
of NEFRON also relied on the GP's assessment of each
patient, which may be inaccurate with regards to assigned
ethnicity or other factors associated with diabetes man-
agement. As a clinic-based incident-driven study it has a
number of limitations, being inherently (and deliber-
ately) biased towards the kind of patients that regularly
attend their practitioner, and the non-standardised labo-
ratory results on which they base their daily management.
Nonetheless, from the practitioner's perspective, the like-
lihood that any routine GP-patient encounter will be
accompanied by specific complications of diabetes, and
the opportunities for improvement within the context of
established practice may be better estimated by a clinic-
based survey, when compared to cross-sectional popula-
The unadjusted frequency of macrovascular disease, stratified  according to age and ethnicity Figure 4
The unadjusted frequency of macrovascular disease, stratified 
according to age and ethnicity. I = Indigenous, NI = Non-
Indigenous, TN = total NEFRON cohort. Error bar denotes 
95% confidence interval
The unadjusted frequency of (a) CKD, stratified according to  age and ethnicity Figure 3
The unadjusted frequency of (a) CKD, stratified according to 
age and ethnicity. Crosshatch denotes patients with an ele-
vated ACR, shading denotes patients with an eGFR < 60 mol/
min/1.73 m2, I = Indigenous, NI = Non-Indigenous, TN = 
total NEFRON cohort. Error bar denotes 95% confidence 
interval for CKD.
The frequency of an elevated urinary ACR (± 95% CI), strati- fied according to duration of diabetes Figure 2
The frequency of an elevated urinary ACR (± 95% CI), strati-
fied according to duration of diabetes. Dark squares denote 
Indigenous patients, white triangles denotes the total 
NEFRON cohort.BMC Public Health 2007, 7:303 http://www.biomedcentral.com/1471-2458/7/303
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tion studies including individuals who are never seen by
practitioners, and data not available to practitioners.
However, as Indigenous patients are less likely to seek care
from a General Practitioner (Family Physician), there
could be a bias towards more unwell subjects in that
group, including those with a history of cardiovascular or
kidney complications. Equally non-compliant individuals
who carry a greater burden of complications, may be less
likely to be represented in an encounter-driven survey.
Nonetheless, the percentage of NEFRON patients with an
Indigenous background (3.7%) was similar to that
observed in other recent cross-sectional studies, including
the DEMAND and the AusDiab surveys (3%) where eth-
nicity was self-identified (Robert Atkins, personal com-
munication).
Although every effort was undertaken to ensure a repre-
sentative distribution of practices through random selec-
tion of investigators[6,7], initial recruitment in the
NEFRON study was also based on interest in undertaking
the study. It is also possible that these clinics might there-
fore not be an accurate representation of primary care
services accessed by Indigenous Australians with diabetes.
Consequently some selection bias in relation to partici-
pating investigators and subsequently enrolled diabetic
patients, cannot be ruled out. Nonetheless, the practice
and practitioner characteristics of the NEFRON study
investigators, were similar to that recorded for Australian
general practice as a whole, and on the whole represent
the 10,000 encounters between patients with type 2 dia-
betes and their GP that occur every working day in Aus-
tralia.
While the NEFRON study shows that ethnic disparities
persist even within the same practice, this survey did not
include individual data on socio-economic, educational,
cultural and other factors known to impact diabetes man-
agement. Poverty, lack of education and other factors
associated with socio-economic disadvantage are strongly
linked to adverse health outcomes, independent to eth-
nicity. However, Indigenous Australian's carry a much
greater burden. As seen in other minority populations
worldwide[16], socio-economic disadvantage is strongly
correlated with the higher prevalence of chronic disease
seen in Aboriginal peoples [17,18]. Data from the com-
munity-based Fremantle Diabetes study suggest that
major disparities in income, housing and eduction may
underlie many of the ethnic differences in diabetes
care[11]. Similarly, issues regarding acceptability, uptake
and compliance have not been addressed in the NEFRON
study. However, recent data suggest that uniform access to
and quality of care can result reduce process or outcome
disparities in diabetes care[4]. While such data have not
been confirmed in Indigenous Australians, even after
adjusting for practice differences by analysing consecutive
patients, key areas of unmet need in Indigenous patients
with type 2 diabetes attending their GP may be clearly
demonstrated.
Albuminuria was more common in Indigenous patients
in this survey, where 23% of patients with type 2 diabetes
had an ACR in the macroalbuminuric range, compared to
6% of non-indigenous individuals. However, the
NEFRON study was limited by restricting classification of
the UAE to the most recent ACR for any individual
patient, Since there is known to be significant day-to-day
variability in albumin excretion, ideally, at least two of
three collections in a 3- to 6-month period should show
elevated levels before a patient is classified as having an
abnormal albumin excretion. Nevertheless, the NEFRON
data are consistent with findings from the AusDiab study,
which employed three collections and found that 34% of
individuals with diabetes had an elevated UAE[19].
Although there is strong familial clustering of CKD in
Indigenous patients, some of the observed excess in CKD
may be attributable to modifiable differences in health
care delivery, including glycaemic control and smoking
cessation [20,21]. There were no clear differences in mean
blood pressure control or the initiation or use of antihy-
pertensive therapy. Indeed, blood pressure targets were
more often achieved in Indigenous patients, consistent
with previous reports [11]. Similarly, the measures of
obesity were similar in Indigenous and non-Indigenous
cohorts, although such parameters have not been vali-
dated in Indigenous Australians.
It has been argued that micro- and macro-albuminuria in
Aboriginal people is common in the absence of diabetes.
Indeed, it has been suggested that the 'normal' range for
microalbuminuria and other variables may be different in
Indigenous and non-indigenous groups. Nonetheless,
from a practitioner's perspective, the finding of CKD in
Indigenous patient with diabetes is a potent risk factor for
adverse outcomes, and should not be dismissed as a racial
difference. While a date of diagnosis of diabetes is not the
same as the onset of diabetes (which is likely to have been
at least 5–10 years earlier), our data suggests that similar
numbers of Indigenous and non-Indigenous patients with
recently diagnosed diabetes had an abnormal ACR,
defined according to conventional guidelines. However,
at later time-points, albuminuria was more common,
potentially reflecting accelerated microvascular disease in
Indigenous patients.
Although microvascular disease was more common in
Indigenous patients, the frequency of patients with mac-
rovascular disease or impaired kidney function was over-
all very similar to that observed in non-Indigenous
patients. Such data may suggest a survival bias, whereby
Indigenous patients who have died or attended tertiaryBMC Public Health 2007, 7:303 http://www.biomedcentral.com/1471-2458/7/303
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hospitals because of more severe complications (e.g.
ESRD, CHF), would not have been included in the
NEFRON study. Indeed, Indigenous patients with type 2
diabetes were on average 11 years younger than non-
Indigenous probands, making cardiovascular events and
ESRD appear less common, though at the same time, after
age adjustment, inordinately high (figure 4). Moreover,
43% of Indigenous patients with type 2 diabetes had a
first degree relative with cardiovascular disease diagnosed
before the age of fifty.
There are many potential contributors to impaired glycae-
mic control in Indigenous patients. Although from the
NEFRON survey it is apparently that patients are receiving
the same combinations of the same antidiabetic drugs,
and the targets for optimal glycaemic control are the same,
few Indigenous patients are reaching these targets. Com-
pliance with prescribed antidiabetic therapies, lifestyle
and dietary modifications are likely contributors to this
disparity, possibly reflecting issues surrounding the fre-
quency, accessibility, affordability, and cultural sensitivity
of diabetic care. Genetic predisposition, dyslipidemia,
chronic inflammation and reduced 'endowment' of pan-
creatic islets (much as nephrons) in low-birth weight
babies, may also make diabetes more difficult to treat. It is
interesting to note that racial differences in metabolic con-
trol diminished with the duration of diabetes. Whether
this is a lead-time effect of late diagnosis of diabetes, or
the loss of recalcitrant patients to co-morbid disease
remains to be established by longitudinal studies. How-
ever, it is plausible that at the time of presentation Indig-
enous patients have more advanced β-cell depletion and
higher levels of insulin resistance, making them less sensi-
tive to standard oral antidiabetic therapies, in a similar
way described in Caucasian populations with advanced
disease[22]. This has led to the suggestion that both
groups would potentially benefit from insulin ther-
apy[11], a treatment approach which remains underuti-
lised in the general practice management of type 2
diabetes.
The NEFRON study was designed to examine factors that
influence the management of diabetes in the context of
GP-patient encounter. As such, it does not address the piv-
otal socio-economic determinates of health, including
income and social status; social support networks; educa-
tion and literacy; employment and working conditions;
social environments; physical environments; and hous-
ing; which also contribute to high rates of diabetes and its
complications. It is clear that Indigenous Australians
Islanders will not achieve equal health outcomes until
their economic, educational and social disadvantages
have been eliminated[23]. Nevertheless, while social dis-
advantage continues, the NEFRON study also demon-
strates key ethnic disparities in Australian diabetes care.
The aim of the national health care funding system is to
give universal access to health care. Yet while seeing the
same doctors and receiving the same medications, treat-
ment targets remain unfulfilled in Indigenous patients.
More importantly, intensification of management, which
should follow the identification of risk, is seldom applied.
This cross-sectional study confirms Aboriginal ethnicity as
a powerful risk factor for microvascular and macrovascu-
lar disease, which should be used by practitioners to iden-
tify candidates for more intensive multifactorial
intervention.
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